The clinical effectiveness agency for England and Wales has published draft guidance opposing everolimus as a second-line treatment for advanced renal cell carcinoma, the most common form of kidney cancer, citing cost concerns and insufficient data for overall survival rates.Everolimus has marketing authorization in the United Kingdom, the European Union and the United States as a second-line treatment for advanced kidney cancer following the failure of vascular endothelial growth factor-targeted...